Podcast Episodes
Back to Search
233: How the biotech revolution could come apart at the seams
Our colleague Matthew Herper joins us to discuss his thoughtful, personal story on how the biotech revolution that brought us genome editing, Covid-1…
4 years ago
232: Anti-science at the polls, a biotech odd couple, & the stakes of the midterms
Our colleague Sarah Owermohle joins us to discuss how pandemic shutdowns, Covid-19 vaccines, and the prospect of arresting Anthony Fauci have become …
4 years ago
231: BU's Covid tinkering, FDA on trial, & why it's hard to take drugs off the market
Lawyer and bioethicist Holly Fernandez Lynch joins us to explain a watershed test of the FDA's authority to revoke drug approvals. And STAT's Helen…
4 years ago
230: BIO's messy transition, mRNA's future, & Biogen's next CEO
STAT Washington correspondent Rachel Cohrs joins us to explain the abrupt departure of the CEO of BIO, the lobbying group representing biotech on Cap…
4 years ago
229: Nobels for science, biotech dealmaking, & a friendly FTC
The newest Nobel laureates got their phone calls from Stockholm this week, and STAT science writer Megan Molteni joins us to explain their prize-winn…
4 years ago
228: A surprise success in Alzheimer's and how FDA history seeded modern controversy
Lecanemab, a new Alzheimer's treatment from partners Biogen and Eisai, succeeded in a pivotal clinical trial, and we explain the surprising developme…
4 years, 1 month ago
227: Biden's Covid declaration, twilight of the SPAC, & genome editing 2.0
Heidi Tworek, a professor at the University of British Columbia and expert on public health communication, joins us to discuss President Biden's decl…
4 years, 1 month ago
226: Pharma's telehealth gold mine, the return of the biotech IPO, & a merger deferred
Our colleague Katie Palmer joins us to explain a burgeoning trend in pharmaceutical advertising that has health policy experts alarmed. We also discu…
4 years, 1 month ago
225: Illumina's $8 billion limbo, a new treatment for ALS, & Emirati biotech funding
Our colleague Matthew Herper joins us to discuss how Illumina, the biggest company in genomic sequencing, got into an $8 billion predicament. We also…
4 years, 1 month ago
224: The anti-aging research boom, the Godfather of biotech, & the future of Biogen
Our colleague Megan Molteni joins us to explain the scientific discoveries, rampant hype, and Silicon Valley billions behind the burgeoning field of …
4 years, 2 months ago